Delisting risk is high but the company has taken remedial action (reverse split and hearing request). The stock is likely to remain listed if Nasdaq accepts the compliance plan. Watch for Nasdaq's hearing decision and any further bid price weakness — failure to maintain $1.00 post-split could reignite delisting proceedings.
Price Chart
Executive Summary
Lexaria Bioscience Corp. (LEXX) received a delisting notification from Nasdaq on August 4, 2026, for failing to regain compliance with the $1.00 minimum bid price requirement within the 180-day cure period. The company completed a reverse stock split on August 3, 2026, and its shares now trade above $1.00; it has filed a hearing request to suspend the delisting and expects to remain listed without interruption.
Key Facts
- Nasdaq notified Lexaria of delisting on August 4, 2026, for failure to meet the $1.00 minimum bid price (Rule 5550(a)(2)) within the 180-day compliance period.
- Lexaria completed a reverse stock split on August 3, 2026, and shares subsequently traded above $1.00.
- The company has requested a hearing and paid the required fee to stay delisting and allow additional trading days to regain compliance.
- Management expects to regain compliance before any hearing date and for shares to remain trading on Nasdaq without interruption.
Financial Impact
Reverse stock split executed; delisting risk mitigated if compliance is regained, but no financial figures provided.
Risk Factors
- Nasdaq may deny the hearing request or find the company still non-compliant, leading to actual delisting.
- Post-split stock price could fall below $1.00 again if selling pressure emerges.
- Reverse split typically reduces liquidity and may pressure the stock.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001640334-26-001302 |
| Document: 0001640334-26-001302-index-headers.html | 0001640334-26-001302 |
| Document: 0001640334-26-001302-index.html | 0001640334-26-001302 |
| Document: 0001640334-26-001302.txt | 0001640334-26-001302 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | EFFECT | $2.82 $2.99 | ▼ −6.03% | ▼ −5.74% | $2.92 (−3.55%) |
Oct 1, 2026 25d ago | S-3 | $2.88 $2.77 | ▲ +3.82% | ▲ +4.49% | $2.92 (−1.39%) |
Sep 1, 2026 7w ago | 8-K | $12.48 $13.21 | ▲ +5.85% | ▲ +5.41% | $2.92 (−76.59%) |
Aug 10, 2026 11w ago | 8-K | $5.79 $6.12 | ▼ −5.70% | ▼ −5.45% | $2.92 (+49.57%) |
Jul 30, 2026 12w ago | 8-K | $0.3963 $0.3910 | ▼ −1.34% | ▼ −2.06% | $2.92 (+636.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers